Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00131573
Other study ID # CR-B-002
Secondary ID
Status Completed
Phase Phase 3
First received August 17, 2005
Last updated October 25, 2013
Start date May 2004
Est. completion date December 2012

Study information

Verified date October 2013
Source Boston Scientific Corporation
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The goal of this study is to investigate the safety and effectiveness of a new implanted device designed to treat Urinary Urgency-Frequency Syndrome.


Recruitment information / eligibility

Status Completed
Enrollment 118
Est. completion date December 2012
Est. primary completion date March 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Key Inclusion criteria:

- Age 18 years and above.

- Diagnosed with urinary urgency-frequency syndrome.

- Have no reported history of urethral obstruction/stricture, bladder calculi or bladder tumor.

- Have normal upper urinary tract function.

- Be capable of giving informed consent.

- Be capable and willing to follow all study related procedures.

Key Exclusion Criteria:

- Have any active implantable device regardless of whether stimulation status is ON or OFF.

- Are pregnant as confirmed by a urine pregnancy test or plan to become pregnant during the following 12 month period.

- Less than one year post partum and/or are breast-feeding.

- Have any large passive implant that contains metal located within 30 cm of the chair pad while seated (e.g., hip replacement).

- Have conditions requiring magnetic resonance imaging (MRI) evaluation.

- Have conditions requiring diathermy procedures.

- Have an inability to operate the bion Remote Control and bion Recharging System either by self or caregiver.

- Have diabetes with peripheral nerve involvement or have severe uncontrolled diabetes.

- Have history of coagulopathy or bleeding disorder.

- Have pelvic pain in the absence of voiding dysfunction.

- Have anatomical restrictions such that the study device placement is not possible.

- Are currently participating or have participated within the past 30 days in any clinical investigation involving or impacting urinary or renal function.

- Cannot independently comprehend and complete the questionnaires.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
bion
battery powered bion microstimulator

Locations

Country Name City State
United States Cleveland Clinic Foundation Cleveland Ohio
United States Dallas Center for Pelvic Medicine Dallas Texas
United States Milestone Medical Research Englewood Colorado
United States New York University New York New York
United States Overland Park Regional Medical Center Overland Park Kansas
United States The Pelvic and Sexual Health Institute Philadelphia Pennsylvania
United States William Beaumont Hospital Royal Oak Michigan
United States The Department of Urology, Stanford University Medical Center Stanford California
United States Arizona Health Sciences Center Tucson Arizona
United States Walter Reed Army Medical Center Washington District of Columbia
United States Cornerstone Medical Specialty Center Woodbury Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Boston Scientific Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average Number of Voids Per Day 12 months No
Primary Freedom From Major Complications 5 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04578899 - "The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity" N/A
Active, not recruiting NCT03556891 - Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence N/A
Not yet recruiting NCT05977634 - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder N/A
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Recruiting NCT06201013 - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children N/A
Recruiting NCT03727711 - TPTNS: Home vs Hospital Treatment for Overactive Bladder N/A
Completed NCT00768521 - A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) Phase 1
Completed NCT03625843 - Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing N/A
Completed NCT02211846 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder Phase 1
Completed NCT02857816 - PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB N/A
Completed NCT02835846 - Investigation of the Effect of the Female Urinary Microbiome on Incontinence Phase 4
Withdrawn NCT02320201 - Foot Neuromodulation for Overactive Bladder in Children N/A
Completed NCT02202031 - Controlling Urgency Through Relaxation Exercises N/A
Not yet recruiting NCT01409512 - Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder N/A
Completed NCT01458197 - A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. Phase 2
Completed NCT01437670 - Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin N/A
Not yet recruiting NCT01423838 - Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Phase 4
Terminated NCT01758848 - Physical Therapy for Overactive Bladder N/A
Withdrawn NCT01210859 - Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents N/A
Completed NCT00910520 - Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Phase 3